ReCell approved in China
Thursday, 03 July, 2008
The Chinese State Food and Drug Administration (SFDA) has granted approval to register Avita Medical's (ASX: AVH) ReCell cell harvesting device on the Chinese market.
The product will be marketed by Helicon Group (ASX: HCG), a WA-headquartered pharmaceutical marketing company specialising in introducing registered medical products into niche markets in China.
The SFDA has approved the product concept and the ReCell kit, but Helicon said there were some importation issues to be overcome before it is on the market.
Helicon has also recently acquired the exclusive licensing rights from EUSA Pharma for Collatamp, an implantable collagen device for the delivery of antibiotics to surgical sites, and is preparing a submission to the SFDA for registration.
Avita Medical was formerly known as Clinical Cell Culture.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
